vancomycin has been researched along with opt 80 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Byrne, B; Emery, J; Krulicki, W; Louie, TJ; Mah, M | 1 |
| Spooner, LM; Sullivan, KM | 1 |
| Hsueh, PR; Ko, WC; Liao, CH; Lu, JJ | 1 |
1 review(s) available for vancomycin and opt 80
| Article | Year |
|---|---|
Fidaxomicin: a macrocyclic antibiotic for the management of Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Glycosides; Humans; Microbial Sensitivity Tests; Randomized Controlled Trials as Topic; Treatment Outcome; Vancomycin | 2010 |
1 trial(s) available for vancomycin and opt 80
| Article | Year |
|---|---|
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
Topics: Anti-Bacterial Agents; Bacteroides; Clostridioides difficile; Clostridium Infections; Dose-Response Relationship, Drug; Glycosides; Humans; Vancomycin | 2009 |
1 other study(ies) available for vancomycin and opt 80
| Article | Year |
|---|---|
Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Clostridioides difficile; Fluoroquinolones; Gemifloxacin; Glycosides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Rifamycins; Rifaximin; Taiwan; Vancomycin | 2012 |